{"id":"multi-dose-quadrivalent-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10–30%","effect":"Injection site soreness or erythema"},{"rate":"5–15%","effect":"Myalgia"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Fatigue"},{"rate":"1–5%","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The quadrivalent influenza vaccine contains inactivated viral antigens from four influenza strains (two A subtypes and two B lineages). When administered, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that recognize and neutralize circulating influenza viruses during the flu season.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:17.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT05426174","phase":"PHASE1","title":"Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-06-09","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":233},{"nctId":"NCT05829356","phase":"PHASE1","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-04-12","conditions":"Influenza Immunization","enrollment":159},{"nctId":"NCT05648357","phase":"PHASE4","title":"A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-12-14","conditions":"Influenza, Human","enrollment":250},{"nctId":"NCT04667117","phase":"PHASE4","title":"A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-14","conditions":"Relapsing Multiple Sclerosis","enrollment":63},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT03457194","phase":"","title":"Optimising Protection for Pregnant Women and Infants With Maternal Vaccination","status":"UNKNOWN","sponsor":"Women's and Children's Hospital, Australia","startDate":"2018-08-28","conditions":"Obesity","enrollment":73},{"nctId":"NCT06118151","phase":"PHASE1","title":"Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-04-11","conditions":"Influenza, Influenza Immunization","enrollment":388},{"nctId":"NCT05045144","phase":"PHASE3","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1586},{"nctId":"NCT04559204","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-09-11","conditions":"Influenza, Human, Pneumonia, Pneumococcal","enrollment":1224},{"nctId":"NCT03391193","phase":"PHASE3","title":"Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-12-19","conditions":"Influenza","enrollment":301},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT03718468","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2018-10-30","conditions":"Influenza","enrollment":842},{"nctId":"NCT03020628","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2016-10","conditions":"Influenza, Human","enrollment":171},{"nctId":"NCT02621164","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-09","conditions":"Influenza, Human","enrollment":454}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Multi-dose Quadrivalent Influenza Vaccine","genericName":"Multi-dose Quadrivalent Influenza Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}